Ardelyx (ARDX) News Today $4.51 -0.15 (-3.22%) (As of 09:58 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Ardelyx (NASDAQ:ARDX) Shares Down 6.5% - Here's What HappenedArdelyx (NASDAQ:ARDX) Trading Down 6.5% - Should You Sell?December 17 at 5:24 PM | marketbeat.comArdelyx, Inc. (NASDAQ:ARDX) Stake Boosted by State Street CorpState Street Corp grew its stake in shares of Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 1.5% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,141,850 shares of the biopharmaceutical compDecember 17 at 3:34 AM | marketbeat.comInsider Selling: Ardelyx, Inc. (NASDAQ:ARDX) CEO Sells 25,000 Shares of StockDecember 13, 2024 | insidertrades.comArdelyx, Inc. (NASDAQ:ARDX) Given Consensus Rating of "Moderate Buy" by BrokeragesDecember 12, 2024 | americanbankingnews.comArdelyx, Inc. (NASDAQ:ARDX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesArdelyx, Inc. (NASDAQ:ARDX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight research firms that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issuDecember 12, 2024 | marketbeat.comBNP Paribas Financial Markets Grows Position in Ardelyx, Inc. (NASDAQ:ARDX)BNP Paribas Financial Markets lifted its position in shares of Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 274.3% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 181,387 shares of the biopharmaceutical company's stock after purchasing an additional 132,92December 10, 2024 | marketbeat.comLeerink Partnrs Increases Earnings Estimates for ArdelyxDecember 8, 2024 | americanbankingnews.comPotential Growth for Ardelyx’s Ibsrela Amidst Market VolatilityDecember 7, 2024 | markets.businessinsider.comArdelyx FY2027 EPS Estimate Increased by Leerink PartnrsArdelyx, Inc. (NASDAQ:ARDX - Free Report) - Investment analysts at Leerink Partnrs upped their FY2027 earnings per share estimates for shares of Ardelyx in a research report issued on Wednesday, December 4th. Leerink Partnrs analyst R. Ruiz now expects that the biopharmaceutical company will postDecember 6, 2024 | marketbeat.comRedmile Group LLC Cuts Stock Holdings in Ardelyx, Inc. (NASDAQ:ARDX)Redmile Group LLC reduced its position in shares of Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 11.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,660,763 shares of the biopharmaceutical company's stoDecember 5, 2024 | marketbeat.comArdelyx, Inc. (NASDAQ:ARDX) Shares Sold by Janus Henderson Group PLCJanus Henderson Group PLC trimmed its holdings in Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 17.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 21,529,880 shares of the biopharmaceutical company's stock after selling 4,4December 5, 2024 | marketbeat.comEventide Asset Management LLC Has $51.08 Million Stock Holdings in Ardelyx, Inc. (NASDAQ:ARDX)Eventide Asset Management LLC raised its holdings in shares of Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 11.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 7,413,049 shares of the biopharmaceutical company's stock after acquiring an additional 746,067November 29, 2024 | marketbeat.comVestal Point Capital LP Acquires Shares of 500,000 Ardelyx, Inc. (NASDAQ:ARDX)Vestal Point Capital LP purchased a new stake in shares of Ardelyx, Inc. (NASDAQ:ARDX - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 500,000 shares of the biopharmaceutical company's stoNovember 29, 2024 | marketbeat.comMichael Raab Sells 25,000 Shares of Ardelyx, Inc. (NASDAQ:ARDX) StockNovember 28, 2024 | insidertrades.comRubric Capital Management LP Buys 1,243,606 Shares of Ardelyx, Inc. (NASDAQ:ARDX)Rubric Capital Management LP grew its stake in shares of Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 68.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,060,191 shares of the biopharmaceutical company's stock afterNovember 27, 2024 | marketbeat.comPropel Bio Management LLC Has $7.38 Million Position in Ardelyx, Inc. (NASDAQ:ARDX)Propel Bio Management LLC raised its position in Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 15.8% during the third quarter, according to its most recent filing with the SEC. The firm owned 1,070,947 shares of the biopharmaceutical company's stock after purchasing an additional 146,364 shares duriNovember 26, 2024 | marketbeat.comArdelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save ItNovember 24, 2024 | seekingalpha.comPrincipal Financial Group Inc. Has $933,000 Stock Position in Ardelyx, Inc. (NASDAQ:ARDX)Principal Financial Group Inc. lessened its holdings in shares of Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 71.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 135,439 shares of the biopharmaceuNovember 24, 2024 | marketbeat.comInsider Selling: Ardelyx, Inc. (NASDAQ:ARDX) CFO Sells 5,260 Shares of StockNovember 23, 2024 | insidertrades.comArdelyx, Inc. (NASDAQ:ARDX) CFO Sells $25,195.40 in StockArdelyx, Inc. (NASDAQ:ARDX - Get Free Report) CFO Justin A. Renz sold 5,260 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $4.79, for a total value of $25,195.40. Following the completion of the transaction, the chief financial officer now owns 291,139 shares of the company's stock, valued at approximately $1,394,555.81. This trade represents a 1.77 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.November 22, 2024 | marketbeat.comArdelyx, Inc. (NASDAQ:ARDX) Insider Laura A. Williams Sells 7,366 SharesArdelyx, Inc. (NASDAQ:ARDX - Get Free Report) insider Laura A. Williams sold 7,366 shares of the firm's stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $4.79, for a total transaction of $35,283.14. Following the completion of the sale, the insider now directly owns 308,745 shares in the company, valued at approximately $1,478,888.55. This trade represents a 2.33 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.November 22, 2024 | marketbeat.comInsider Selling: Ardelyx, Inc. (NASDAQ:ARDX) CEO Sells 31,980 Shares of StockArdelyx, Inc. (NASDAQ:ARDX - Get Free Report) CEO Michael Raab sold 31,980 shares of the firm's stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $4.79, for a total value of $153,184.20. Following the completion of the transaction, the chief executive officer now owns 1,175,385 shares in the company, valued at $5,630,094.15. The trade was a 2.65 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.November 22, 2024 | marketbeat.comArdelyx to Participate at the Piper Sandler 36th Annual Healthcare ConferenceNovember 20, 2024 | globenewswire.comArdelyx Appoints Joseph Reilly as Principal Accounting OfficerNovember 18, 2024 | markets.businessinsider.comArdelyx, Inc. (NASDAQ:ARDX) Sees Large Increase in Short InterestArdelyx, Inc. (NASDAQ:ARDX - Get Free Report) was the target of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 24,060,000 shares, an increase of 5.1% from the October 15th total of 22,890,000 shares. Based on an average daily volume of 3,460,000 shares, the short-interest ratio is presently 7.0 days.November 18, 2024 | marketbeat.comArdelyx, Inc. (NASDAQ:ARDX) Given Average Rating of "Moderate Buy" by AnalystsShares of Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eight brokerages that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation, five have assigned a buy recommendatNovember 17, 2024 | marketbeat.comArdelyx (NASDAQ:ARDX) Shares Gap Up - Time to Buy?Ardelyx (NASDAQ:ARDX) Shares Gap Up - What's Next?November 15, 2024 | marketbeat.comArdelyx's Medicare Setback Casts Doubt On Long-Term ViabilityNovember 14, 2024 | seekingalpha.comArdelyx, Inc. (NASDAQ:ARDX) CEO Sells $13,440.70 in StockNovember 13, 2024 | insidertrades.comResearch Analysts Set Expectations for Ardelyx Q1 EarningsArdelyx, Inc. (NASDAQ:ARDX - Free Report) - Stock analysts at HC Wainwright decreased their Q1 2025 earnings estimates for shares of Ardelyx in a research report issued to clients and investors on Monday, November 11th. HC Wainwright analyst E. Arce now anticipates that the biopharmaceutical compNovember 13, 2024 | marketbeat.comHC Wainwright & Co. Downgrades Ardelyx (ARDX)November 12, 2024 | msn.comArdelyx downgraded to Neutral from Buy at H.C. WainwrightNovember 12, 2024 | markets.businessinsider.comArdelyx down as H.C. Wainwright downgrades rating on anticipated Xphozah sales dropNovember 12, 2024 | msn.comArdelyx (NASDAQ:ARDX) Sees Unusually-High Trading Volume - What's Next?Ardelyx (NASDAQ:ARDX) Sees Large Volume Increase - Time to Buy?November 11, 2024 | marketbeat.comArdelyx (NASDAQ:ARDX) Rating Lowered to Neutral at HC WainwrightHC Wainwright downgraded Ardelyx from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $11.00 to $5.50 in a report on Monday.November 11, 2024 | marketbeat.comArdelyx down 21% to $5.30 after judge dismisses lawsuit against CMSNovember 9, 2024 | markets.businessinsider.comArdelyx tumbles as lawsuit against CMS dismissed over Xphozah (update)November 9, 2024 | msn.comInsider Selling: Ardelyx, Inc. (NASDAQ:ARDX) Insider Sells 27,171 Shares of StockNovember 9, 2024 | insidertrades.comDavid P. Rosenbaum Sells 27,171 Shares of Ardelyx, Inc. (NASDAQ:ARDX) StockArdelyx, Inc. (NASDAQ:ARDX - Get Free Report) insider David P. Rosenbaum sold 27,171 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $6.10, for a total value of $165,743.10. Following the completion of the sale, the insider now directly owns 153,616 shares of the company's stock, valued at approximately $937,057.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.November 8, 2024 | marketbeat.comArdelyx Responds to District Court Decision Granting Motion to DismissNovember 8, 2024 | globenewswire.comArdelyx (NASDAQ:ARDX) Shares Gap Down - What's Next?Ardelyx (NASDAQ:ARDX) Shares Gap Down - Time to Sell?November 8, 2024 | marketbeat.comInsider Selling: Ardelyx, Inc. (NASDAQ:ARDX) Insider Sells 27,172 Shares of StockNovember 7, 2024 | insidertrades.comArdelyx’s Strong Sales and Strategic Positioning Reinforce Buy Rating Amid Reimbursement UncertaintiesNovember 5, 2024 | markets.businessinsider.comArdelyx to Participate at the 2024 Jefferies London Healthcare ConferenceNovember 5, 2024 | globenewswire.comCitigroup Has Lowered Expectations for Ardelyx (NASDAQ:ARDX) Stock PriceCitigroup cut their price objective on Ardelyx from $12.00 to $10.00 and set a "buy" rating on the stock in a research report on Monday.November 4, 2024 | marketbeat.comWedbush Research Analysts Cut Earnings Estimates for ArdelyxArdelyx, Inc. (NASDAQ:ARDX - Free Report) - Equities research analysts at Wedbush reduced their FY2026 earnings per share estimates for Ardelyx in a report issued on Friday, November 1st. Wedbush analyst L. Chico now expects that the biopharmaceutical company will post earnings per share of $0.06November 4, 2024 | marketbeat.comArdelyx, Inc.: Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 3, 2024 | finanznachrichten.deArdelyx Third Quarter 2024 Earnings: US$0.003 loss per share (vs US$0.03 profit in 3Q 2023)November 3, 2024 | finance.yahoo.comArdelyx, Inc. (NASDAQ:ARDX) Q3 2024 Earnings Call TranscriptNovember 2, 2024 | msn.comQ3 2024 Ardelyx Inc Earnings CallNovember 2, 2024 | finance.yahoo.com Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Will the Nasdaq 100 crash? (Ad)In a world where some top money managers say you should “diversify” with a basket of stocks to help lower risk in your portfolio… And others say you should focus on only one ticker at a time because you can’t really keep detailed tabs on 10, 20 or more stocks at once… My #1 strategy to play the Nasdaq bull run has shown the power to provide the best of BOTH worlds at the same time. Because it harnesses ONE ticker that bottles up all the firepower of Apple, Nvidia, Tesla and more into one place… While I cannot promise future returns or against losses… This strategy targets major payouts OVERNIGHT! Click here to get the details. ARDX Media Mentions By Week ARDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARDX News Sentiment▼0.330.65▲Average Medical News Sentiment ARDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARDX Articles This Week▼68▲ARDX Articles Average Week Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CRNX News Today KRYS News Today ACLX News Today ADMA News Today RARE News Today BHVN News Today APLS News Today IMVT News Today SRRK News Today RNA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARDX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
